Nicholson RI - Search Results

1

Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.

Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI. Knowlden JM, et al. Among authors: nicholson ri. Endocrinology. 2003 Mar;144(3):1032-44. doi: 10.1210/en.2002-220620. Endocrinology. 2003. PMID: 12586780

2

Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization.

Gee JM, Nicholson RI. Gee JM, et al. Among authors: nicholson ri. Breast Cancer Res. 2003;5(3):126-9. doi: 10.1186/bcr584. Epub 2003 Feb 20. Breast Cancer Res. 2003. PMID: 12793892 Free PMC article. Review.

3

Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.

Hutcheson IR, Knowlden JM, Madden TA, Barrow D, Gee JM, Wakeling AE, Nicholson RI. Hutcheson IR, et al. Among authors: nicholson ri. Breast Cancer Res Treat. 2003 Sep;81(1):81-93. doi: 10.1023/A:1025484908380. Breast Cancer Res Treat. 2003. PMID: 14531500

4

The biology of antihormone failure in breast cancer.

Nicholson RI, Gee JM, Knowlden J, McClelland R, Madden TA, Barrow D, Hutcheson I. Nicholson RI, et al. Breast Cancer Res Treat. 2003;80 Suppl 1:S29-34; discussion S35. doi: 10.1023/a:1025467500433. Breast Cancer Res Treat. 2003. PMID: 14535532 Review.

5

Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination.

Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JM. Nicholson RI, et al. Clin Cancer Res. 2004 Jan 1;10(1 Pt 2):346S-54S. doi: 10.1158/1078-0432.ccr-031206. Clin Cancer Res. 2004. PMID: 14734490

6

Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.

Jordan NJ, Gee JM, Barrow D, Wakeling AE, Nicholson RI. Jordan NJ, et al. Among authors: nicholson ri. Breast Cancer Res Treat. 2004 Sep;87(2):167-80. doi: 10.1023/B:BREA.0000041623.21338.47. Breast Cancer Res Treat. 2004. PMID: 15377841

7

Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839).

Hiscox S, Morgan L, Barrow D, Dutkowskil C, Wakeling A, Nicholson RI. Hiscox S, et al. Among authors: nicholson ri. Clin Exp Metastasis. 2004;21(3):201-12. doi: 10.1023/b:clin.0000037697.76011.1d. Clin Exp Metastasis. 2004. PMID: 15387370

8

Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model.

Staka CM, Nicholson RI, Gee JM. Staka CM, et al. Among authors: nicholson ri. Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S85-97. doi: 10.1677/erc.1.01006. Endocr Relat Cancer. 2005. PMID: 16113102

9

Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.

Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI. Hiscox S, et al. Among authors: nicholson ri. Breast Cancer Res Treat. 2006 Jun;97(3):263-74. doi: 10.1007/s10549-005-9120-9. Epub 2005 Dec 7. Breast Cancer Res Treat. 2006. PMID: 16333527

10

Growth factor receptor interplay and resistance in cancer.

Jones HE, Gee JM, Hutcheson IR, Knowlden JM, Barrow D, Nicholson RI. Jones HE, et al. Among authors: nicholson ri. Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S45-51. doi: 10.1677/erc.1.01275. Endocr Relat Cancer. 2006. PMID: 17259558 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

294 results

Search Page

Filters